Day: September 24, 2025

Applied is leveraging its leadership in materials engineering to provide the highest quality waveguides for augmented reality glasses SANTA CLARA, Calif. and SINGAPORE, Sept. 23, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced a strategic collaboration with GlobalFoundries (GF) to establish a state-of-the-art waveguide fabrication facility at GF Singapore to accelerate the emerging photonics inflection driven by AI. The collaboration marks a significant milestone in the evolution of photonics as a foundational technology for next-generation AI applications, including augmented reality (AR) and human-centric digital experiences that require ultra-efficient, lightweight and high-performance optical systems. Applied Materials will develop waveguide components with GF as its high-volume manufacturing partner in Singapore,...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67.67 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 960,542 shares of common stock at the purchase price of $67.669 per pre-funded warrant, which represents the offering price per share for the common stock less a $0.001 per share exercise price. The gross proceeds to Monopar from the offering net of the anticipated Stock Repurchase (as defined below), but before deducting the underwriting...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (link), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. In the Letter to the Editor, the authors explain that the earlier conclusion from the Phase 2 ALXN1840-WD-204 study (NCT04573309)...

VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC; OTC: ZCTSF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced private placement financing by issuing a total of 38,449,335 units (“Units”) at a price of $0.06 per Unit for gross proceeds of $2,306,960. The Company anticipates it will complete the final tranche by September 29, 2025. Each Unit consists of one common share (a “Share”) and one common share purchase warrant (a “Warrant”), with each Warrant exercisable at $0.10 per Share for a period of two years from the date of issue (the “Expiry Date”). The Company has the right to accelerate the Expiry Date if, at any time, the volume weighted average price of the Shares on the principal exchange or market on which the Shares trade...

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) — Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “Irish Takeover Rules”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the “Proxy Statement”) and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) and Mural entered into a definitive transaction agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued...